Early detection is crucial in the battle against breast cancer. This systematic review explores the potential of artificial intelligence (AI) in predicting future breast cancer risk using mammograms. We analyze existing studies to evaluate the accuracy, reliability, and clinical implications of AI-driven risk assessment models. By understanding the strengths and limitations of these models, we aim to inform future research and clinical practice.
Breast cancer remains a significant public health concern worldwide. Early detection through regular mammograms has been instrumental in reducing mortality rates. However, mammograms have limitations in predicting future cancer risk. Recent advancements in artificial intelligence (AI) offer promising opportunities to improve breast cancer risk assessment. This review delves into the current state of AI-driven mammography-based breast cancer risk prediction models.
Artificial intelligence has made remarkable strides in various fields, including healthcare. In radiology, AI algorithms have demonstrated exceptional performance in detecting abnormalities in medical images. Specifically, AI-powered mammogram analysis has shown promise in identifying subtle signs of breast cancer that might be missed by human radiologists.
Beyond detecting existing cancers, AI has the potential to predict the likelihood of developing breast cancer in the future. By analyzing mammographic images, AI algorithms can identify subtle patterns and features associated with increased risk. These models could be used to prioritize screening, target preventive interventions, and ultimately reduce breast cancer mortality.
To conduct this review, we systematically searched relevant databases for studies investigating AI-driven mammography-based breast cancer risk prediction. Inclusion and exclusion criteria were defined to ensure the quality and relevance of included studies. The extracted data included study design, sample size, AI algorithm, performance metrics, and clinical implications.
The included studies demonstrated varying levels of accuracy in predicting breast cancer risk using AI-driven mammogram analysis. Several factors influenced model performance, including the type of AI algorithm, dataset size, and image quality. While some studies reported promising results, further research is needed to validate these findings in larger and more diverse populations.
The integration of AI-driven breast cancer risk prediction models into clinical practice could revolutionize preventive care. By identifying women at higher risk, healthcare providers can offer tailored screening and prevention strategies. However, challenges such as model interpretability, ethical considerations, and patient acceptance must be addressed.
AI-driven mammography-based breast cancer risk prediction holds significant promise for improving early detection and prevention. While the field is still in its early stages, the potential benefits are substantial. Continued research and development are essential to refine these models and translate them into clinical practice. By harnessing the power of AI, we can move closer to a future where breast cancer is a preventable disease.
1.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
2.
Do Anatomy Atlases Reflect Social Inequalities?
3.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
4.
Some triple negative breast cancers might be avoided by longer breastfeeding
5.
Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances
3.
Ferroptosis-Modulating Nanocarriers for Solid Tumor Therapy
4.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
5.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Excellence in Hematology
2.
Navigating the Complexities of Ph Negative ALL - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Understanding the causes of anemia in adults beyond nutritional deficiencies
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation